IL7R and melanoma: In addition, expression of IL-7R and/or the IL-7R pathway is significantly greater in immune checkpoint inhibitors (ICI) responders versus non-responders in melanoma, NSCLC, ovarian, TNBC, HNSCC, and/or kidney malignancies (112).